Abstract
Late detection of osteosarcoma with metastases complicates staging, limits treatment tactics, and worsens clinical outcomes; therefore, it is important to determine the practical value of early diagnostic tools. The aim of the study was to assess the relationship between modern imaging methods, biopsy results, and treatment effectiveness. Based on a diagnostic cohort analysis, clinical data were reviewed sequentially, and the results of computed tomography, magnetic resonance imaging, chest computed tomography, bone scintigraphy or PET/CT, as well as biopsy, were compared with staging indicators. The combined interpretation of imaging and morphological examination results increased diagnostic accuracy and made it possible to adapt treatment decisions to the clinical stage. Accuracy according to the established diagnostic criteria was 76.2 %; indicators associated with individual examinations were recorded at levels of 42.9 % and 33.3 %. The difference between diagnostic accuracy and treatment effectiveness was assessed at the p<0.001 level, while the other observed statistical thresholds were p<0.05 and p=0.018. The results indicate the need to integrate early imaging, biopsy, and chest examination into a single algorithm. The scientific contribution of the study consists in substantiating the practical relationship between staging and therapeutic decisions in osteosarcoma as a unified diagnostic approach. At the next stage, standardized multicenter follow-up should examine the independent effect of this accuracy on overall and disease-free survival.
References
1. Ritter J., Bielack S.S. Osteosarcoma // Annals of Oncology. — 2010. — Vol. 21, Suppl. 7. — P. vii320–vii325. — DOI: 10.1093/annonc/mdq276.
2. Isakoff M.S., Bielack S.S., Meltzer P., Gorlick R. Osteosarcoma: current treatment and a collaborative pathway to success // Journal of Clinical Oncology. — 2015. — Vol. 33, № 27. — P. 3029–3035. — DOI: 10.1200/JCO.2014.59.4895.
3. Kansara M., Teng M.W.L., Smyth M.J., Rosenberg A.E. Translational biology of osteosarcoma // Nature Reviews Cancer. — 2014. — Vol. 14, № 11. — P. 722–735. — DOI: 10.1038/nrc3838.
4. Gill J., Gorlick R. Advancing therapy for osteosarcoma // Nature Reviews Clinical Oncology. — 2021. — Vol. 18, № 10. — P. 609–624. — DOI: 10.1038/s41571-021-00519-8.
5. Smeland S., Bruland Ø.S., Hjorth L., et al. Survival and prognosis with osteosarcoma: results from the EURAMOS-1 good responder randomized trial // European Journal of Cancer. — 2019. — Vol. 109. — P. 36–50. — DOI: 10.1016/j.ejca.2018.12.013.
6. Marina N., Gebhardt M., Teot L., Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma // The Oncologist. — 2004. — Vol. 9, № 4. — P. 422–441. — DOI: 10.1634/theoncologist.9-4-422.
7. Bacci G., Bertoni F., Longhi A., et al. Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli experience // European Journal of Cancer. — 2005. — Vol. 41, № 18. — P. 2836–2845. — DOI: 10.1016/j.ejca.2005.08.026.
8. Bielack S.S., Kempf-Bielack B., Delling G., et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols // Journal of Clinical Oncology. — 2002. — Vol. 20, № 3. — P. 776–790. — DOI: 10.1200/JCO.2002.20.3.776.
9. Bacci G., Mercuri M., Briccoli A. Prognostic factors in osteosarcoma: a critical review // Journal of Clinical Oncology. — 1994. — Vol. 12, № 2. — P. 423–431. — DOI: 10.1200/JCO.1994.12.2.423.
10. Picci P., Bacci G., Campanacci M., et al. Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy: regional mapping of viable and nonviable tumor // Cancer. — 1985. — Vol. 56, № 7. — P. 1515–1521. — DOI: 10.1002/1097-0142(19851001)56:7<1515::AID-CNCR2820560710>3.0.CO;2-6.
11. Costelloe C.M., Madewell J.E., Ta L.K., et al. Imaging bone tumors: current status and future directions // Radiology. — 2013. — Vol. 268, № 1. — P. 47–65. — DOI: 10.1148/radiol.13121732.
12. Hongtao L., Hui Z., Yao W., et al. The value of diffusion-weighted magnetic resonance imaging in the diagnosis and evaluation of osteosarcoma // European Journal of Radiology. — 2019. — Vol. 116. — P. 1–7. — DOI: 10.1016/j.ejrad.2019.04.012.
13. O'Connor M.I., Binitie O., Letson G.D., et al. The role of MRI in the local staging of osteosarcoma // Clinical Orthopaedics and Related Research. — 2015. — Vol. 473, № 3. — P. 842–850. — DOI: 10.1007/s11999-014-4014-5.
14. Bajpai J., Chandrasekharan A., Talreja V., et al. The role of 18F-FDG PET/CT in osteosarcoma: a systematic review and meta-analysis // European Journal of Nuclear Medicine and Molecular Imaging. — 2021. — Vol. 48, № 8. — P. 2525–2538. — DOI: 10.1007/s00259-020-05155-7.
15. Im H.J., Zhang Y., Wu H., et al. Prognostic value of metabolic tumor volume and total lesion glycolysis in osteosarcoma: a systematic review and meta-analysis // European Journal of Nuclear Medicine and Molecular Imaging. — 2020. — Vol. 47, № 5. — P. 1135–1146. — DOI: 10.1007/s00259-019-04625-5.
16. Strauss S.J., Frezza A.M., Abecassis N., et al. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up // Annals of Oncology. — 2021. — Vol. 32, № 12. — P. 1520–1536. — DOI: 10.1016/j.annonc.2021.08.1995.
17. Casali P.G., Abecassis N., Bauer S., et al. Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up // Annals of Oncology. — 2022. — Vol. 33, № 2. — P. 134–148. — DOI: 10.1016/j.annonc.2021.09.006.
18. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Bone Cancer. Version 2.2024 [Elektron resurs]. — URL: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418 (murojaat sanasi: 16.10.2026).
19. WHO Classification of Tumours Editorial Board. Soft Tissue and Bone Tumours. 5th ed. — Lyon: International Agency for Research on Cancer, 2020. — 608 p. — ISBN 978-92-832-4502-5.
20. Мирошниченко В.В., Губкин А.В., Коваленко И.В. Современные подходы к диагностике и лечению остеосаркомы // Саркомы костей, мягких тканей и опухоли кожи. — 2021. — № 3. — С. 12–20.
21. Тепляков В.В., Бердюгин К.А., Карпенко В.Ю. Остеосаркома: современные принципы диагностики и лечения // Онкология. Журнал им. П.А. Герцена. — 2020. — Т. 9, № 5. — С. 45–53.
22. Ахмедов Б.Б., Нурматов Ш.К., Рахматуллаев Ж.А. Современная диагностика и комплексное лечение остеосаркомы // Ўзбекистон онкология журнали. — 2021. — № 2. — С. 28–35.
23. Абдуллаева Д.А., Саидова М.М., Мирзаева Н.Т. Значение ранней диагностики в повышении эффективности лечения остеосаркомы // Тиббиётда янги кун. — 2022. — № 4. — С. 112–118.
24. Геворкян А.А., Мусаев Э.Р., Бохян Б.Ю. Роль лучевых методов исследования в диагностике остеосаркомы // Российский онкологический журнал. — 2019. — Т. 24, № 4. — С. 186–192.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.